The objective of the study is to critically review the literature about clinical evidence on the efficacy and safety of fitusiran among patients with hemophilia A or B.
Data sources:
A targeted search of PubMed, Embase, the Cochrane Library, and ClinicalTrials.gov was performed from inception through November 2025 using the terms fitusiran, antithrombin, RNA interference, siRNA, and hemophilia A or B.
Study selection and data extraction:
Eligible studies were randomized controlled trials across all phases enrolling patients with hemophilia A or B. The review incorporated 2 phase 1 studies, 1 phase 2 study, and 4 phase 3 trials.
Data synthesis:
Fitusiran prophylaxis reduced annualized bleeding rates by about 70% to 90% compared with on-demand therapy or previous prophylaxis using bypassing agents, and by up to 50% compared with prior prophylaxis with clotting factor concentrates. Between 50% and 65% of participants experienced no bleeds requiring treatment. Health-related quality of life improved, with mean reductions in Hemophilia-specific Quality of Life Questionnaire for Adults (Haem-A-QoL) scores ranging from −4.6 to −12.3. Safety evaluations showed aminotransferase elevations in 19% to 25%, gallbladder events in 13% to 15%, and thrombotic events in ≤5% of patients, primarily associated with low antithrombin levels or excessive factor use. Long-term extension studies confirmed sustained bleed protection and safety with antithrombin-guided dosing.
Relevance to patient care and clinical practice in comparison to existing drugs:
Fitusiran is a subcutaneous nonfactor prophylactic treatment that lowers antithrombin to rebalance coagulation with or without inhibitors in patients with hemophilia A and B. It is administered every 2 months, and associated with fewer bleeds, and improved quality of life compared with standard of care.
Conclusions:
Fitusiran expands prophylactic options for hemophilia A and B, providing sustained bleed protection with infrequent dosing. Integration into practice requires monitoring of antithrombin activity to mitigate thrombotic or bleeding risk, and liver and gallbladder functions for safety.
SpadarellaGDi MinnoAMilanG, et al. Paradigm shift for the treatment of hereditary haemophilia: towards precision medicine. Blood Rev. 2020;39:100618. doi:10.1016/j.blre.2019.100618
2.
Pelland-MarcotteMCCarcaoMD.Hemophilia in a changing treatment landscape. Hematol Oncol Clin North Am. 2019;33(3):409-423. doi:10.1016/j.hoc.2019.01.007
3.
LillicrapDFijnvandraatKYoungGMancusoME.Patients with hemophilia A and inhibitors: prevention and evolving treatment paradigms. Expert Rev Hematol. 2020;13(4):313-321. doi:10.1080/17474086.2020.1739518
4.
FranchiniMMannucciPM.Non-factor replacement therapy for haemophilia: a current update. Blood Transfus. 2018;16(5):457-461. doi:10.2450/2018.0272-17
5.
CastamanGLinariS.Current and emerging biologics for the treatment of hemophilia. Expert Opin Biol Ther. 2019;19(8):801-810. doi:10.1080/14712598.2019.1614163
6.
NogamiKShimaM.Current and future therapies for haemophilia-beyond factor replacement therapies. Br J Haematol. 2023;200(1):23-34. doi:10.1111/bjh.18379
7.
Jiménez-YusteVAuerswaldGBensonG, et al. Practical considerations for nonfactor-replacement therapies in the treatment of haemophilia with inhibitors. Haemophilia. 2021;27(3):340-350. doi:10.1111/hae.14167
8.
MancusoMECroteauSEKlamrothR.Benefits and risks of non-factor therapies: redefining haemophilia treatment goals in the era of new technologies. Haemophilia. 2024;30(suppl 3):39-44. doi:10.1111/hae.14976
9.
NogamiKShimaM.New therapies using nonfactor products for patients with hemophilia and inhibitors. Blood. 2019;133(5):399-406. doi:10.1182/blood-2018-07-820712
10.
SidonioRFJrHoffmanMKenetGDargaudY.Thrombin generation and implications for hemophilia therapies: a narrative review. Res Pract Thromb Haemost. 2022;7(1):100018. doi:10.1016/j.rpth.2022.100018
11.
LuDDouFGaoJ.Fitusiran: the first approved siRNA therapy for hemophilia via reducing plasma antithrombin levels. Drug Discov Ther. 2025;19(2):131-132. doi:10.5582/ddt.2025.01031
12.
MachinNRagniMV.An investigational RNAi therapeutic targeting antithrombin for the treatment of hemophilia A and B. J Blood Med. 2018;9:135-140. doi:10.2147/JBM.S159297
13.
BoyceSRangarajanS.RNAi for the treatment of people with hemophilia: current evidence and patient selection. J Blood Med. 2023;14:317-327. doi:10.2147/JBM.S390521
14.
LeeA.Fitusiran: first approval. Drugs. 2025;85(8):1073-1077. doi:10.1007/s40265-025-02203-y
15.
YoungGLentingPJCroteauSENolanBSrivastavaA.Antithrombin lowering in hemophilia: a closer look at fitusiran. Res Pract Thromb Haemost. 2023;7(4):100179. doi:10.1016/j.rpth.2023.100179
ChowdaryPAngchaisuksiriPApteS, et al. Concizumab prophylaxis in people with haemophilia A or haemophilia B without inhibitors (explorer8): a prospective, multicentre, open-label, randomised, phase 3a trial. Lancet Haematol. 2024;11(12):e891-e904. doi:10.1016/S2352-3026(24)00307-7
18.
SrivastavaARangarajanSKavakliK, et al. Fitusiran prophylaxis in people with severe haemophilia A or haemophilia B without inhibitors (ATLAS-A/B): a multicentre, open-label, randomised, phase 3 trial. Lancet Haematol. 2023;10(5):e192-e202. doi:10.1016/S2352-3026(23)00037-6
19.
YoungGSrivastavaAKavakliK, et al. Efficacy and safety of fitusiran prophylaxis in people with haemophilia A or haemophilia B with inhibitors (ATLAS-INH): a multicentre, open-label, randomised phase 3 trial. Lancet. 2023;401(10386):1427-1437. doi:10.1016/S0140-6736(23)00284-2
20.
KenetGNolanBZulfikarB, et al. Fitusiran prophylaxis in people with hemophilia A or B who switched from prior BPA/CFC prophylaxis: the ATLAS-PPX trial. Blood. 2024;143(22):2256-2269. doi:10.1182/blood.2023021864
21.
YoungGKavakliKKlamrothR, et al. Safety and efficacy of a fitusiran antithrombin-based dose regimen in people with hemophilia A or B: the ATLAS-OLE study. Blood. 2025;145(25):2966-2977. doi:10.1182/blood.2024027008
22.
ClinicalTrials.gov. Fitusiran prophylaxis in male pediatric subjects aged 1 to less than 12 years with hemophilia A or B (ATLAS-PEDS). Accessed September 15, 2025. https://clinicaltrials.gov/ct2/show/NCT03974113
23.
ClinicalTrials.gov. A study to test a medicine (fitusiran) injected under the skin for preventing bleeding episodes in male adolescent or adult participants with severe hemophilia (ATLAS-NEO). Accessed September 15, 2025. https://clinicaltrials.gov/ct2/show/NCT05662319
24.
PasiKJRangarajanSGeorgievP, et al. Targeting of antithrombin in hemophilia A or B with RNAi therapy. N Engl J Med. 2017;377(9):819-828. doi:10.1056/NEJMoa1616569
25.
PasiKJLissitchkovTMamonovV, et al. Targeting of antithrombin in hemophilia A or B with investigational siRNA therapeutic fitusiran-results of the phase 1 inhibitor cohort. J Thromb Haemost. 2021;19(6):1436-1446. doi:10.1111/jth.15270
26.
PipeSWLissitchkovTGeorgievP, et al. Long-term safety and efficacy of fitusiran prophylaxis, and perioperative management, in people with hemophilia A or B. Blood Adv. 2025;9(5):1147-1158. doi:10.1182/bloodadvances.2024013900
OlasupoOONoronhaNLoweMSAnselDBhattMMatinoD.Non-clotting factor therapies for preventing bleeds in people with congenital hemophilia A or B. Cochrane Database Syst Rev. 2024;2:CD014544. doi:10.1002/14651858.CD014544.pub2
29.
SrivastavaASantagostinoEDougallA, et al. WFH guidelines for the management of hemophilia, 3rd edition.Haemophilia. 2020;26(suppl 6):1-158. doi:10.1111/hae.14046
MahlanguJOldenburgJPaz-PrielI, et al. Emicizumab prophylaxis in patients who have hemophilia A without inhibitors. N Engl J Med. 2018;379(9):811-822. doi:10.1056/NEJMoa1803550
ShapiroADAngchaisuksiriPAstermarkJ, et al. Efficacy and safety of concizumab prophylaxis in hemophilia A and hemophilia B with inhibitors (explorer7): a multicentre, open-label, randomized, phase 3 trial. Blood Adv. 2023;7(3):387-398. doi:10.1182/bloodadvances.2022008457
MatinoDAcharyaSPalladinoA, et al. Marstacimab prophylaxis in hemophilia A/B without inhibitors (BASIS): results from the phase 3 trial. Blood. 2024;146(14):1654-1663. doi:10.1182/blood.2024027468
36.
ChowdaryPAngchaisuksiriPApteS, et al. Concizumab prophylaxis in people with haemophilia A or haemophilia B without inhibitors (explorer8): a prospective, multicentre, open-label, randomised, phase 3a trial. Lancet Haematol. 2024;11(12):e891-e904. doi:10.1016/S2352-3026(24)00307-7. Erratum in: Lancet Haematol. 2024;11(12):e886. doi:10.1016/S2352-3026(24)00353-3
37.
CallaghanMUNegrierCPaz-PrielI, et al. Long-term outcomes with emicizumab prophylaxis for hemophilia A with or without FVIII inhibitors: results from the HAVEN 1-4 studies. Blood. 2021;137(16):2231-2242. doi:10.1182/blood.2020009217
